Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.
Tim Cortese
Advertisement
Articles by Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
Energy Insecurity Linked to Higher Depression, Anxiety in US Adults
5
